Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions

A GLP-2, peptibody technology, applied in the direction of fusion polypeptide, hybrid peptide, fusion of prolonging plasma life, etc., can solve the problem that GLP-2 does not show the prospect

Pending Publication Date: 2020-05-19
SHIRE NPS PHARM INC
View PDF18 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, administration of GLP-2 itself to human patients has not shown promise

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
  • Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
  • Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions

Examples

Experimental program
Comparison scheme
Effect test

example

[0321] The invention is also described and illustrated by means of the following examples. However, the use of these and other examples anywhere in the specification is illustrative only and in no way limits the scope and meaning of the invention or of any exemplified term. Likewise, the invention is not limited to any particularly preferred embodiments described herein. In fact, many modifications and variations of the present invention will be apparent to those skilled in the art from reading the present description, and such variations can be made without departing from the spirit or scope of the invention. The invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which those claims are entitled.

example 1

[0322] Example 1: Molecular weight and FcRn binding of GLP-2 peptibody

[0323] Binding to the Fc neonatal receptor (FcRN) allows for recycling of the molecule and results in prolonged serum half-life of Fc fusion proteins in vivo. Recycling occurs when molecules are passively taken up into the cell and the pH of the endosome is low. This results in binding of the Fc portion of the molecule to FcRN. When FcRN is recycled back to the cell surface, the pH is then neutralized and the protein is released back into the serum.

[0324] Binding to the extracellular domain of FcRN was measured by surface plasmon resonance (SPR) using a Biacore system. Direct attachment with FcRn was achieved via amine coupling of CM5 chips to FcRn under the following conditions:

[0325] i) Dilute hFcRn (self-expressed and purified) to 5 μg / mL in acetate buffer pH 5.0.

[0326] ii) 5 μg / mL FcRn was immobilized on a CM5 chip with a target of 500 RU in PBS pH 7.0

[0327] iii) Final response 454RU ...

example 2

[0335] Example 2: Protein Stability Analysis

[0336] Each of the GLP-2 peptibodies was tested by measuring the melting temperature with nano-differential scanning fluorimetry (NanoDSF). NanoDSF is a temperature ramp measurement of protein stability over a range of temperatures. The stability of tryptophan was measured by fluorescence as reflected by the ratio of fluorescence at 350 nm to fluorescence at 330 nm. Depending on the analysis, one or more melting temperatures are determined. Since a protein in a certain state is understood to have a certain melting temperature, the number of observed melting temperatures reflects the number of different states. GLP-2 peptibodies A, B, E, J, K, L and M have two states, as shown in Table 2 below.

[0337] SEC-MALS analysis was performed to determine the initial state (main peak) and its molecular weight. As shown in Table 2 below, GLP-2 peptibodies A, B, E, J, K, L, M and O (Fc fusions) eluted at molecular weights indicative of d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
lengthaaaaaaaaaa
Login to view more

Abstract

Described are fusion proteins of GLP-2 with an Fc region of immunoglobulin. The GLP-2 and Fc regions are separated by a linker comprised of amino acids. The fusion proteins persist and remain active in the body for longer periods of time than GLP-2 itself. Methods are disclosed of using the fusion proteins to treat and prevent enterocutaneous fistulae, radiation damage to the gastrointestinal tract, obstructive jaundice, and short bowel syndrome.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Application No. 62 / 548,601, filed August 22, 2017, U.S. Provisional Application No. 62 / 621,144, filed January 24, 2018, and U.S. Provisional Application No. 62 / 621,144, filed April 18, 2018. Priority to Provisional Application No. 62 / 659,394, the disclosure of each of which is incorporated herein by reference in its entirety. technical field [0003] The present invention discloses mammalian GLP-2 fusion polypeptides and proteins and their use as therapeutic agents. Background technique [0004] Post-translational processing of proglucagon produces glucagon-like peptide-2 (GLP-2), a 33 amino acid somatotropin hormone. GLP-2 is used to slow gastric emptying, reduce gastric secretions and increase intestinal blood flow. GLP-2 also stimulates the growth and villi length of the large and small intestine to increase the surface area of ​​the mucosal epithelium at least by promotin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/26A61K47/64A61K47/68A61K39/395C07K14/605C07K16/00C07K19/00A61P1/00
CPCC07K14/605C07K16/00A61P1/00C07K2319/30C07K2319/31A61K38/00C07K2319/02C07K2317/92C07K2317/94A61K2039/545A61K47/68
Inventor C·潘A·诺顿B·施特拉克-洛格K·孙
Owner SHIRE NPS PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap